AU2020265327B2 - Method for treating cough by using diaminopyrimidine compound - Google Patents

Method for treating cough by using diaminopyrimidine compound

Info

Publication number
AU2020265327B2
AU2020265327B2 AU2020265327A AU2020265327A AU2020265327B2 AU 2020265327 B2 AU2020265327 B2 AU 2020265327B2 AU 2020265327 A AU2020265327 A AU 2020265327A AU 2020265327 A AU2020265327 A AU 2020265327A AU 2020265327 B2 AU2020265327 B2 AU 2020265327B2
Authority
AU
Australia
Prior art keywords
days
compound
alkylene
saturated
cough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020265327A
Other languages
English (en)
Other versions
AU2020265327A1 (en
Inventor
Ran AN
Huai HUANG
Yuanyuan JIANG
Zhou LAN
Huining LIANG
Yanan Liu
Hongjun Wang
Jin Wang
Yanping Zhao
Liying Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of AU2020265327A1 publication Critical patent/AU2020265327A1/en
Application granted granted Critical
Publication of AU2020265327B2 publication Critical patent/AU2020265327B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020265327A 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound Active AU2020265327B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/085180 2019-04-30
CN2019085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗咳嗽的方法

Publications (2)

Publication Number Publication Date
AU2020265327A1 AU2020265327A1 (en) 2021-12-16
AU2020265327B2 true AU2020265327B2 (en) 2025-09-11

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020265327A Active AU2020265327B2 (en) 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound

Country Status (12)

Country Link
US (1) US20220211703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3960179B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665529B2 (cg-RX-API-DMAC7.html)
KR (1) KR102935436B1 (cg-RX-API-DMAC7.html)
CN (1) CN114007619B (cg-RX-API-DMAC7.html)
AU (1) AU2020265327B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021600A2 (cg-RX-API-DMAC7.html)
ES (1) ES3067370T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021013338A (cg-RX-API-DMAC7.html)
SG (1) SG11202111877TA (cg-RX-API-DMAC7.html)
TW (1) TWI736243B (cg-RX-API-DMAC7.html)
WO (1) WO2020221274A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途
WO2019085916A1 (zh) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1725540E (pt) * 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
DK2343281T3 (en) 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
PE20160431A1 (es) * 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CA2998742C (en) * 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
AU2017237929B2 (en) * 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途
WO2019085916A1 (zh) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAYID ABDULQAWI ET AL: "P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study", THE LANCET (2015), 385 (9974), pages 1198 - 1205, DOI: 10.1016/S0140-6736(14)61255-1 *

Also Published As

Publication number Publication date
ES3067370T3 (en) 2026-05-21
JP7665529B2 (ja) 2025-04-21
JP2022530890A (ja) 2022-07-04
KR102935436B1 (ko) 2026-03-05
SG11202111877TA (en) 2021-11-29
MX2021013338A (es) 2022-01-24
BR112021021600A2 (pt) 2022-01-04
TWI736243B (zh) 2021-08-11
EP3960179A1 (en) 2022-03-02
KR20220007620A (ko) 2022-01-18
US20220211703A1 (en) 2022-07-07
AU2020265327A1 (en) 2021-12-16
CN114007619B (zh) 2024-08-06
EP3960179B1 (en) 2026-03-18
CN114007619A (zh) 2022-02-01
TW202106302A (zh) 2021-02-16
EP3960179A4 (en) 2023-01-25
CA3138780A1 (en) 2020-11-05
WO2020221274A1 (zh) 2020-11-05

Similar Documents

Publication Publication Date Title
AU2020305979B2 (en) Method for treating idiopathic pulmonary fibrosis
AU2020230574B2 (en) Method for treating fatty liver disease and/or steatohepatitis
WO2022206985A1 (zh) 一种环状酮类化合物的新用途
AU2020266947B2 (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
KR102935436B1 (ko) 디아미노피리미딘 화합물을 사용한 기침 치료 방법
JPH0269417A (ja) 精神分裂病治療用組成物
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
CA3138780C (en) Method for treating cough by using diaminopyrimidine compound
US20080312253A1 (en) Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40062124B (en) Method for treating cough by using diaminopyrimidine compound
US20260137682A1 (en) Method for treating pneumoconiosis
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
MX2024009372A (es) Sales de adicion de acidos, composiciones y metodos de tratamiento de las mismas.
HK40063168B (en) Method for treating cough by using diaminopyrimidine compound
JPS61267520A (ja) 医薬組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)